1Lok ASF, McMahon BJ. AASLD practice guidline: Chronic hepatitis B: Update of recommendations. Hepatology, 2004,39:857-861.
2Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on management of chronic hepatitis B: an update.Hepatology, 2003, 18:239-245.
3Yuen MF, Wang KH,Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological,and clinical aspects. Hepatology, 2004, 39 : 1694-1701.
4Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatits B. Hepatology, 2003, 37:748-755.
5Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat, 2002, 9:208-212.
6van Numen AB, Hansen BE, Sub DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase, Gut2003,52:420-424.
7McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis, 2004,24 : 17-21.
8Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone and in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroneterology, 2004,126:91-101.
9Han CL. Results of a one-year international phase Ⅱb trial hepatitis 15. J Hepatol, 2004, 40:16.
